IS7811A - Methods and test materials for the treatment of diseases and disorders associated with increased levels of inflammatory cell messengers - Google Patents

Methods and test materials for the treatment of diseases and disorders associated with increased levels of inflammatory cell messengers

Info

Publication number
IS7811A
IS7811A IS7811A IS7811A IS7811A IS 7811 A IS7811 A IS 7811A IS 7811 A IS7811 A IS 7811A IS 7811 A IS7811 A IS 7811A IS 7811 A IS7811 A IS 7811A
Authority
IS
Iceland
Prior art keywords
diseases
treatment
methods
disorders associated
increased levels
Prior art date
Application number
IS7811A
Other languages
Icelandic (is)
Inventor
Manivasakam Palaniyandi
Smith Brendan
Fong Jason
A. Auspitz Benjamin
James Nichols M.
Keith Curtis
R. Zimmermann Grant
B. Brasher Bradley
Sachs Noah
W. Chappell Todd
Grau Daniel
Roydon Jost-Price Edward
Original Assignee
Combinatorx, Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32074779&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS7811(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Combinatorx, Incorporated filed Critical Combinatorx, Incorporated
Publication of IS7811A publication Critical patent/IS7811A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IS7811A 2002-09-24 2005-04-19 Methods and test materials for the treatment of diseases and disorders associated with increased levels of inflammatory cell messengers IS7811A (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US41304002P 2002-09-24 2002-09-24
US41726102P 2002-10-09 2002-10-09
US42742402P 2002-11-19 2002-11-19
US42752602P 2002-11-19 2002-11-19
US46475303P 2003-04-23 2003-04-23
PCT/US2003/030156 WO2004030618A2 (en) 2002-09-24 2003-09-24 Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines

Publications (1)

Publication Number Publication Date
IS7811A true IS7811A (en) 2005-04-19

Family

ID=32074779

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7811A IS7811A (en) 2002-09-24 2005-04-19 Methods and test materials for the treatment of diseases and disorders associated with increased levels of inflammatory cell messengers

Country Status (12)

Country Link
EP (1) EP1553955A4 (en)
JP (1) JP2006503905A (en)
AR (1) AR041386A1 (en)
AU (1) AU2003299196A1 (en)
BR (1) BR0314713A (en)
CA (1) CA2509526A1 (en)
HR (1) HRP20050355A2 (en)
IS (1) IS7811A (en)
MX (1) MXPA05003152A (en)
NO (1) NO20051669L (en)
TW (1) TW200422042A (en)
WO (1) WO2004030618A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05008649A (en) * 2003-02-14 2005-11-23 Combinatorx Inc Combination therapy for the treatment of immunoinflammatory disorders.
AU2004275777A1 (en) * 2003-09-24 2005-04-07 Combinatorx, Incorporated Therapeutic regimens for administering drug combinations
CA2566861A1 (en) * 2004-05-17 2005-12-08 Combinatorx, Incorporated Methods and reagents for the treatment of immunoinflammatory disorders
BRPI0517847A (en) * 2004-11-19 2008-10-21 Organon Nv combination, uses of a selective serotonin reuptake inhibitor and a glucocorticoid receptor antagonist, and method for the treatment of an individual of a vertebrate species suffering from depression or a related disorder.
AU2011236053B2 (en) * 2004-11-19 2014-06-26 Merck Sharpe & Dohme B.V. Drug combination comprising a selective serotonin reuptake inhibitor and a glucocorticoid receptor antagonist for the treatment of depression
ATE473735T1 (en) * 2005-04-13 2010-07-15 Astion Dev As BETA-2 ADRENOCEPTOR AGONISTS FOR THE TREATMENT OF CONNECTIVE TISSUE DISEASES OF THE SKIN
JP4832806B2 (en) * 2005-06-03 2011-12-07 久光製薬株式会社 Transdermal formulation
TW200711649A (en) * 2005-06-17 2007-04-01 Combinatorx Inc Combination therapy for the treatment of immunoinflammatory disorders
WO2008031014A1 (en) * 2006-09-08 2008-03-13 Ore Pharmaceuticals Inc. Method for reducing or alleviating inflammation in the digestive tract
US20080064709A1 (en) * 2006-09-11 2008-03-13 Duke University Methods and compositions for the treatment of vascular depression
GB0701171D0 (en) * 2007-01-22 2007-02-28 Imp Innovations Ltd Compositions and uses thereof
WO2010098230A1 (en) * 2009-02-27 2010-09-02 久光製薬株式会社 Transdermal preparation
PT117765B (en) * 2022-01-28 2025-04-04 Faculdade De Farmacia Da Univ De Lisboa TOPICAL FORMULATION OF FLUVOXAMINE FOR THE TREATMENT OF PSORIASIS
TW202423434A (en) * 2022-10-07 2024-06-16 瑞士商歐庫利斯營運股份有限公司 Eye drop microsuspensions of mtor inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU674292B2 (en) * 1991-10-15 1996-12-19 Immunex Corporation Methods and compositions for treating allergic reactions
GB9603137D0 (en) * 1996-02-15 1996-04-17 Merck Sharp & Dohme Therapeutic agents
DE69735656T2 (en) * 1996-07-15 2006-08-24 Alza Corp., Mountain View Device for the transdermal administration of fluoxetine
PL336464A1 (en) * 1997-03-18 2000-06-19 Basf Ag Method of and compositions for modulating reactivity in respect to corticosteroids i
US6281248B1 (en) * 2000-02-16 2001-08-28 Magda Abdel Fattah Ahmed Composition for treating asthma
IL139975A0 (en) * 2000-11-29 2002-02-10 Univ Ramot Anti proliferative drugs

Also Published As

Publication number Publication date
TW200422042A (en) 2004-11-01
AU2003299196A1 (en) 2004-04-23
CA2509526A1 (en) 2004-04-15
JP2006503905A (en) 2006-02-02
EP1553955A4 (en) 2008-11-05
MXPA05003152A (en) 2006-04-27
AR041386A1 (en) 2005-05-18
NO20051669L (en) 2005-06-10
HRP20050355A2 (en) 2005-10-31
BR0314713A (en) 2005-07-26
EP1553955A2 (en) 2005-07-20
WO2004030618A2 (en) 2004-04-15
WO2004030618A3 (en) 2005-04-07

Similar Documents

Publication Publication Date Title
IS8410A (en) Methods and Reagents for the Treatment of Immune Inflammatory Disorders
DK1888033T3 (en) Method and composition for the treatment of inflammatory diseases
CY2021009I2 (en) ANTI-P-SELECTIN ANTIBODIES AND METHODS OF USING THEM IN THE TREATMENT OF INFLAMMATORY DISEASES
IL183827A0 (en) Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders
DK1889065T3 (en) METHODS OF DIAGNOSIS AND TREATMENT OF DISEASES WITH AN AUTO-IMMUNE AND / OR INFLAMMATION COMPONENT
DK1644021T3 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISEASES
DK1755743T3 (en) Beta-hydroxybutyrate and derivatives for the treatment of depression and anxiety
SI1608374T1 (en) 2-phenoxy- and 2-phenylsulfomamide derivatives with ccr3 antagonistic activity for the treatment of asthma and other inflammatory or immunological disorders
DK1626728T3 (en) Oxidized lipids and their use in the treatment of inflammatory diseases and disorders
DK1765322T3 (en) Retinal derivatives and methods for their use in the treatment of visual disorders
DK1805312T3 (en) Methods and agents for the preparation of hyaluronan
IS7811A (en) Methods and test materials for the treatment of diseases and disorders associated with increased levels of inflammatory cell messengers
DK1663978T3 (en) Fluoro-substituted omega-carboxyaryl-diphenylurea for the treatment and prevention of diseases and disorders
DK2308507T3 (en) Methods for the treatment of preeclampsia
DE602005003186D1 (en) Fluoropolymer and its use
PL381765A1 (en) Fixing constructions and the method of their application
IL180251A0 (en) Methods and reagents for the treatment of metabolic disorders
EP1811935A4 (en) THERMOSETTING GEL AND METHOD OF MANUFACTURING THE SAME
EP1746902A4 (en) MULTILEKTIN AFFINICHROMATOGRAPHY AND USE THEREOF
DK1487828T3 (en) Morpholinyl-urea derivatives for use in the treatment of inflammatory diseases
ITMI20050704A1 (en) SEMICONDUCTOR DEVICE AND METHOD OF PRODUCTION OF THE SAME
DK1701944T3 (en) 2- (amino-substituted) -4-aryl pyramidines and related compounds for the treatment of inflammatory diseases
DK1478438T3 (en) Methods and compositions for the treatment of asthma
DK1952103T3 (en) Method of weighing with multiple weighing cells
DK1589973T4 (en) Formulation and methods for the treatment of thrombocythaemia